Waters shareholders approve transformative BD business combination
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Waters ( (WAT) ) has issued an announcement.
On January 27, 2026, Waters shareholders overwhelmingly approved the issuance of Waters common stock to shareholders of Becton, Dickinson and Company in connection with the planned combination of BD’s Biosciences & Diagnostic Solutions business with Waters, with approximately 90.8% of eligible shares represented at the special meeting and about 99% of those present voting in favor. With all required regulatory approvals secured and a favorable IRS private letter ruling obtained on U.S. federal income tax matters related to the deal, the companies expect to close the transaction on February 9, 2026, positioning Waters as a more differentiated leader in life sciences and diagnostics and prompting the company to align the release of its Q4 2025 financial results and conference call with the anticipated closing date.
The most recent analyst rating on (WAT) stock is a Buy with a $460.00 price target. To see the full list of analyst forecasts on Waters stock, see the WAT Stock Forecast page.
Spark’s Take on WAT Stock
According to Spark, TipRanks’ AI Analyst, WAT is a Outperform.
The score is driven by strong earnings-call momentum (raised guidance and above-guidance EPS) and solid underlying profitability/returns, with supportive price action above key moving averages. These positives are tempered by premium valuation (high P/E), mixed cash flow dynamics, and incremental execution risk around the pending BD-related transaction and associated legal proceedings.
To see Spark’s full report on WAT stock, click here.
More about Waters
Waters Corporation (NYSE: WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for more than 65 years. With over 7,600 employees in more than 100 countries, the company focuses on ensuring the efficacy of medicines, the safety of food and water, and the quality and sustainability of everyday products for customers in laboratories, manufacturing sites, and hospitals worldwide.
Average Trading Volume: 558,221
Technical Sentiment Signal: Strong Buy
Current Market Cap: $23.28B
See more data about WAT stock on TipRanks’ Stock Analysis page.
